NCT06825559View on ClinicalTrials.gov

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Cholestatic Liver Disease
Interventions
DRUG

Saroglitazar Magnesium 1 mg

Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in this open label study

Trial Locations (1)

46202

Zydus Site US001, Indianapolis

All Listed Sponsors
lead

Zydus Therapeutics Inc.

INDUSTRY

NCT06825559 - Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease | Biotech Hunter | Biotech Hunter